NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...

Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

These moves will enable the gene-editing company to focus resources on late-stage programs as it aims to launch a commercial product by 2027, it said.

Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.

In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...

Vivo’s X200, along with the X200 Pro, is the latest entry in its flagship X series, and it’s not here to play second fiddle. Vivo is aiming straight for the heavyweights—Apple and Samsung—with a ...

Vivo is currently working on the X200 Ultra New foldable phone could debut in June or July in China Vivo's S-branded flagship could launch in the first half of next year ...

Last week, Xiaomi confirmed that the Redmi Turbo 4 will be the first phone to be powered by the latest MediaTek Dimensity 8400-Ultra SoC. Now the smartphone has surfaced in Geekbench listing with the ...

A timeline of “2025-2026” was therefore set for the launch. Vivo Nex 3, a 2019 production-grade phone with no bezels on two sides. Vivo Unlike certain Chinese brands that have attempted to ...

OnePlus just introduced the Ace 5 and Ace 5 Pro smartphones in the Ace series in China, as it had promised. The phones pack a 1.5K 1.5K BOE X2 flat screen, self-developed Display P2 chip and up to ...